One of the largest trials to investigate a CYP2C19 genotype-guided strategy to guide antiplatelet choice has found no benefit when applied to clopidogrel and ticagrelor after PCI. The TAILOR-PCI study, which enrolled 5,302 patients requiring 12 months of antiplatelet therapy after PCI, failed to show any benefit from selecting therapy based on the presence of ...
Genotype tailoring of antiplatelet therapy provides no benefit: PCI study
By Michael Woodhead
30 Mar 2020